During the second quarter, we made decisive
progress in the commercialization of our ground-
breaking point-of-care (POC) diagnostic platform,
with the high-sensitivity troponin test set to be the
first product launched. With intial positive results
from our whole blood study, a fully subscribed rights
issue, and record interest from potential international
commercial partners, we are now stronger than ever.

A key achievement during the quarter was the initial
results from the ongoing whole blood study at St
Thomas’ Hospital in London. The results show clear
equivalence between whole blood and plasma,
confirming that our Psyros POC system delivers
the same high clinical performance regardless of
sample type. This is another important milestone that
reduces the risks for the planned clinical performance study required for regulatory approval in the EU
and further strengthens our position in discussions
with potential commercial partners.

At the same time, we secured our financial position
through a fully subscribed rights issue – with strong
participation from the board, management, and ITL,
our contract manufacturing partner for the instrument. The high level of commitment demonstrates
strong confidence in the company and our strategy,
enabling cost-effective financing without the need
for underwriters. The capital raised gives us the flexibility we need to successfully complete development, intensify commercial partner discussions, and initiate the regulatory clinical performance study in 2025, without financial pressure.

During the quarter, we also welcomed our new chairman of the board, Fredrik Alpsten. With extensive experience from senior positions in international diagnostics, our new chairman brings valuable expertise and a strong network to help take Psyros to the global market.

Our presence at the international congress ADLM (Association for Diagnostics & Laboratory Medicine & Clinical Lab Expo) in Chicago at the end of July was a milestone in itself. Our fully operational commercial prototype attracted substantial international attention – many visitors took the opportunity to explore the system firsthand and experience its performance and ease of use. Interest has grown significantly following the positive results from our biobank and whole blood studies, confirming that our solution is perfectly timed for the market. Meeting potential commercial partners and future users who could personally witness the system’s performance and usability was both rewarding and inspiring.

Overall, the second quarter has been marked by successful scientific results, a strengthened financial
foundation, and growing interest from commercial partners. Combined with our unique, proprietary POC technology – which enables single-molecule counting in a portable format – a strong IP portfolio (further strengthened during the quarter), and a dedicated team, we are now well equipped for the continued journey toward commercialization.

We continue to create value for our shareholders by providing fast, accurate point of care system that
contribute to quicker diagnoses and appropriate treatment that saves lives.

Lund August 28 2025

Ulf bladin

CEO Prolight Diagnostics (publ)